Compare Enveric Biosciences Inc (ENVB) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while State Street SPDR S&P Homebuilders ETF trades at $94.83 (market cap $1.49B). The key difference: State Street SPDR S&P Homebuilders ETF is far larger — about 219.1× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 2,445,587). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| ENVB | XHB | |
|---|---|---|
Market Cap | $6.80M | $1.49B |
Volume | 64,867 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $121.36 |
52-Week Low | $1.27 | $94.86 |
Typical Hold Time | 14 Days | 33 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.65, down 0.25% on the day. Technical indicators are bearish, with moving averages signaling sell pressure and oscillators neutral. The ETF tracks the homebuilding sector, which faces headwinds from high mortgage rates but potential tailwinds from new housing affordability legislation and institutional interest.
The outlook for XHB is mixed, balancing sector-specific risks like rising rates against legislative support and valuation opportunities. Investment appeal hinges on a housing market recovery, with risks including economic sensitivity and inventory constraints. Sentiment is cautious but notes historical buying signals at current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
